

CURRICULUM VITAE

Bryon D. Johnson PhD

Adjunct Professor
Department of Medicine
Division of Hematology and Oncology - Medicine

OFFICE ADDRESS:

Froedtert Hospital
9200 W Wisconsin Ave
Milwaukee, WI 53226

EDUCATION:

08/1979 - 05/1983 BS, Iowa State University, Ames, IA
08/1983 - 05/1989 PhD, The University of Health Sciences/The Chicago Medical School (now Rosalind Franklin University), North Chicago, IL

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

08/1989 - 06/1992 Postdoctoral Fellow, Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI
07/1992 - 06/1993 Senior Research Associate, Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI

MILITARY SERVICE:

None

FACULTY APPOINTMENTS:

07/1993 - 06/1994 Instructor, Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI
07/1994 - 06/2001 Assistant Professor, Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI
07/2001 - 06/2008 Associate Professor, Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI
07/2008 - Present Professor, Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI
01/2009 - Present Secondary Appointment, Professor, Microbiology & Molecular Genetics, Medical College of Wisconsin, Milwaukee, WI

RESEARCH ADMINISTRATIVE APPOINTMENTS:

11/2005 - Present Chair, Pediatric Oncology Translational Immunotherapy Group, Medical College of Wisconsin, Milwaukee, WI
2010 - Present Chair, Institutional Animal Care and Use Committee (IACUC), Medical College of Wisconsin, Milwaukee, WI
2012 - Present Member, Pediatric Hematology-Oncology-Transplant Leadership Team (Research Representative), Medical College of Wisconsin, Milwaukee, WI

AWARDS AND HONORS:

1999 Recipient of Best Abstracts Award, American Society for Blood and Marrow Transplantation (ASBMT) Annual Meeting, Miami Beach, FL
2000 Ernest McCulloch and James Till Award for the best science article in Biology of Blood and Marrow Transplantation by a new investigator, American Society for Blood and Marrow Transplantation

(ASBMT) Annual Meeting, Anaheim, CA
2011 Teaching Award for contributions to the Medical Microbiology Course, Medical College of Wisconsin
2013 Teaching Excellence Award for work in the Medical Student Physician Scientist Pathway, Medical College of Wisconsin

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:

The Chicago Medical School Chapter of the Sigma Xi Scientific Research Society (1992)
American Society for Blood and Marrow Transplantation (ASBMT)
Federation of Clinical Immunology Societies (FOCIS)
International Society for Biological Therapy of Cancer (iSBTC)
Society for Immunotherapy of Cancer (SITC)
American Society of Hematology (ASH)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:

Editorship

2010 - Present Associate Editor, Biology of Blood and Marrow Transplantation

Editorial Board

2001 - 2010 Biology of Blood and Marrow Transplantation

Journal Review

Biology of Blood and Marrow Transplantation

Cellular Immunology

Haematologica

Journal of Clinical Investigation

Stem Cells

Clinical Immunology

Science Translational Medicine

Journal of Pediatric Hematology Oncology

Cancer Research

Disease Markers and Cancer Biomarkers

Clinical Cancer Research

Expert Reviews of Vaccines

Advances In Cancer Research

Immunology

Cancer Immunology Immunotherapy

Cytokine

Bone Marrow Transplantation

Blood

Journal of Immunotherapy

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

1994 Grant Reviewer, The Israel Academy of Sciences and Humanities

1997 - 1999 Grant Reviewer, Special Emphasis Panel, NIH

1999 Grant Reviewer, Merit Review Award Program, VA

2002 - 2003 Grant Reviewer, Special Panel, NIH

2002 Member, Program Project Site Visits, NIH/NCI

2002 - 2003 Abstract Reviewer, Coordinating Reviewer, Oral Abstract Session Co-Chair (2003), Annual Meeting, American Society of Hematology

2002 - 2004 Grant Reviewer, Special Emphasis Panel, NIH

2004 Member, Program Project Site Visits, NIH/NCI

2005 Ad hoc Member, Subcommittee D - Clinical Studies Review Committee, NIH/NCI

2005 Member, Program Project Cluster Review, NIH/NCI

2005 Co-Chair, Annual Meeting Workshop, American Society of Blood and Marrow Transplantation

2005 - 2007 Ad hoc Member, Cancer Immunopathology and Immunotherapy (CII) Study Section, NCI

2005 Ad hoc Member, Transplantation Tolerance and Tumor Immunology (TTT) Study Section, NCI

2008 Abstract Reviewer & Coordinating Reviewer, Annual Meeting, American Society of Hematology

2009 - Present Representative, Federation of Clinical Immunology Societies (FOCIS), American Society for Blood and Marrow Transplantation

2009 - 2013 Ad hoc Member, Cancer Immunopathology and Immunotherapy (CII) Study Section, NCI
 2010 - 2012 Grant Reviewer, Special Emphasis Panel, NIH
 2010 Ad hoc Reviewer, Children 's Research Institute Pilot Innovative Research Grant Applications, Medical College of Wisconsin
 2011 Member, Strategic Planning "Goal A" Task Force, Society of Immunotherapy of Cancer (SITC)
 2011 - Present Member, ZRG1-OTC-C(2) Special Emphasis Study Section, NIH
 2013 Member, Cancer Immunopathology and Immunotherapy (Cil), NCI
 2014 Ad hoc Reviewer, Children 's Research Institute Pilot Innovative Research Grant Applications, Medical College of Wisconsin

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:

Active

Peer Review

Title:	Optimizing Immunotherapy for Neuroblastoma after BMT
Source:	NIH/NCI (R01 CA100030-07)
Role & Effort:	Principal Investigator
PI:	Bryon Johnson, PhD
Dates:	2009 - 2015
Title:	Transient Lymphodepletion and PD-1/PD-L1 Blockade to Treat Myeloma
Source:	Multiple Myeloma Research Foundation
Role & Effort:	Principal Investigator
Dates:	2012 - 2015
Direct Funds:	\$181,818 (Total)
Title:	Use of TERT Vaccine in Prevention of Lung Cancer in Animal Models
Source:	Board of Regents of the University of Oklahoma (NIH subcontract)
Role & Effort:	Co-Investigator
Dates:	09/23/2013 - 09/22/2015
Direct Funds:	\$308,174
Title:	Expansion of T Cells from the Marrow of Cancer Patients for Adoptive Cell Therapy
Source:	Children's Research Institute
Role & Effort:	PI
Dates:	01/01/2015 - 12/31/2015
Direct Funds:	\$50,000
Title:	A Novel Immunotherapy Targeting Acute Myeloid Leukemia
Source:	Children's Research Institute
Role & Effort:	Co-PI
Dates:	01/01/2015 - 12/31/2015
Direct Funds:	\$50,000

Non-Peer Review

Title:	General research support awarded on an annual basis through contributions to the Midwest Children's Cancer Center
Source:	Midwest Athletes Against Childhood

Role & Effort: Cancer (MACC) Fund
Principal Investigator
PI: Bryon Johnson, PhD
Dates: 07/2012 - 06/2015
Direct Funds: \$35,000

Prior

Peer Review

Title: Manipulation of GVL/GVH Reactions
after Allogeneic BMT
Source: NIH/NCI
Role & Effort: Co-Investigator
PI: Robert Truitt, PhD
Dates: 1992 - 1995
Direct Funds: \$373,000 (total for all years)

Title: Reconstitution of the Thymus after Non-
TBI Pretransplant Conditioning for
Allogeneic BMT and its Impact on
Tolerance Induction, GVHD and GVL
Reactivities
Source: American Cancer Society Institutional
Research Grant
Role & Effort: Principal Investigator
PI: B. Johnson
Dates: 1994 - 1995
Direct Funds: \$10,000

Title: DLI Therapy and BMT: Effector and
Regulatory Mechanisms
Source: NIH/NCI
Role & Effort: Principal Investigator
PI: B. Johnson
Dates: 1996 - 2001
Direct Funds: \$349,091 (total for all years)

Title: Mechanisms of Successful Therapy of
GVHD with MoAb
Source: NIH/NCI
Role & Effort: Co-Investigator
PI: R. Truitt
Dates: 1997 - 2002
Direct Funds: \$761,559 (total for all years)

Title: Fused Neuroblastoma and Dendritic
Cells as a Tumor Vaccine
Source: Children's Hospital Foundation,
Children's Hospital of Wisconsin
Role & Effort: Co-Principal Investigator
Dates: 1999 - 2000
Direct Funds: \$40,670

Title: CD4 Regulatory T Cells Suppress
Alloreactivity after BMT
Source: NIH/NCI
Role & Effort: Principal Investigator

Dates:	2001 - 2006
Direct Funds:	\$787,500 (total for all years)
Title:	Allospecific Immunoregulatory T Cells in BMT Recipients
Source:	Medical College of Wisconsin Cancer Center Interdisciplinary Grant
Role & Effort:	Principal Investigator
PI:	B. Johnson
Dates:	2001 - 2002
Direct Funds:	\$25,000
Title:	Transfection of Immune Co-stimulatory Molecules in Head and Neck Cancer Cells
Source:	American Cancer Society Institutional Grant
Role & Effort:	Co-Investigator
PI:	R. Orentas
Dates:	2003 - 2004
Direct Funds:	\$25,000
Title:	Coexpression of the T Cell Chemoattractant Lymphotoxin and Costimulatory Molecules CD80 and CD86 in a Neuroblastoma Tumor Vaccine
Source:	American Cancer Society Institutional Grant
Role & Effort:	Co-Investigator
PI:	B. Volkman
Dates:	2003 - 2004
Direct Funds:	\$25,000
Title:	Optimizing Immunotherapy for Neuroblastoma after BMT
Source:	NIH/NCI (R01 CA100030)
Role & Effort:	Principal Investigator
PI:	B. Johnson
Dates:	2004 - 2009
Direct Funds:	\$194,378 (per year)
Title:	Cell-Based Vaccines Derived from Patient Cancers
Source:	Wisconsin Breast Cancer Showhouse
Role & Effort:	Co-Investigator
PI:	R. Orentas
Dates:	2005 - 2007
Direct Funds:	\$150,000 (total for all years)
Title:	Immunotherapy for Myeloma Early after Hematopoietic Stem Cell Transplantation
Source:	Medical College of Wisconsin Cancer Center
Role & Effort:	Principal Investigator
PI:	B. Johnson

Dates:	2006 - 2007
Direct Funds:	\$25,000
Title:	Adoptive T Cell Therapy Against Mammary Tumors
Source:	Wisconsin Breast Cancer Showhouse
Role & Effort:	Co-Investigator
PI:	J. Shilyansky
Dates:	2006 - 2007
Direct Funds:	\$125,000 (total for all years)
Title:	Cell-Based Vaccines for Breast Cancer in the FVB/N (MMTV NEU) Mouse Model
Source:	Wisconsin Breast Cancer Showhouse
Role & Effort:	Co-Investigator
PI:	J. Gershan
Dates:	2008 - 2010
Direct Funds:	\$150,000 (total for all years)
Title:	In Vivo Analysis of Metastatic Progenitor Cells
Source:	American Cancer Society Institutional Pilot Grant
Role & Effort:	Co-Investigator
PI:	Jill Gershan, PhD
Dates:	01/2012 - 12/2012
Direct Funds:	\$30,000
Title:	Tumor Vaccine and Immune Modulating Agents to Optimize Anti-tumor Immunity
Source:	Clinical & Translational Science Institute (CTSI) of Southeast WI
Role & Effort:	Co-Investigator
PI:	J Gershan
Dates:	03/2012 - 12/2012
Direct Funds:	\$20,000
Title:	Introduction of Type I Interferon Responses by Irradiation: A New Tool for Cancer Therapy
Source:	Advancing Healthier Wisconsin
Role & Effort:	Co-Investigator
PI:	V Terakanova
Dates:	03/2012 - 12/2012
Direct Funds:	\$30,000
Title:	Expression of Programmed Death Receptor-1 (PD-1) Ligands on Pediatric Leukemias
Source:	MACC Fund Novel Initiative
Role & Effort:	PI
Dates:	2012 - 2013
Direct Funds:	\$14,265

Non-Peer Review

Title: Interim Funding
Source: Medical College of Wisconsin Cancer Center
Role & Effort: Principal Investigator
PI: B. Johnson
Dates: 1995 - Present
Direct Funds: \$10,000

Title: Lymphohematopoietic Engraftment in Minimally Myeloablated Hosts
Source: Cerus Corporation
Role & Effort: Principal Investigator
PI: B. Johnson
Dates: 1999 - 2000
Direct Funds: \$142,274 (total)

Title: Establishment of an Experimental Treatment Model for Neuroblastoma in the Context of Bone Marrow Transplantation
Source: Children's Hospital Foundation, Children's Hospital of Wisconsin
Role & Effort: Co-Principal Investigator
Dates: 2002 - 2004
Direct Funds: \$56,086 (total for all years)

Title: Translational Studies of Cell-Based Vaccines for Childhood Cancer
Source: Midwest Athletes Against Childhood Cancer (MAACC) Fund
Role & Effort: Co-Investigator
PI: Robert Truitt, PhD
Dates: 2007 - 2010
Direct Funds: \$1,000,000 (total for all years)

Title: Temporal Expression Analysis of PD-1 on T Cells and PD-L1 on Plasma Cells in Bone Marrow from Myeloma Patients
Source: Hematologic Malignancy and Transplantation Cancer Ctr. Program Seed Grant
Role & Effort: Co-Investigator
PI: M. Pasquini
Dates: 2012 - 2013
Direct Funds: \$15,000

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:

International

The Developing Immune System after Stem Cell Transplantation, International Symposium, Ulm, Germany, 02/20/1998 - 02/22/1998

Converging Therapies: The Role of Mixed Chimerism in Transplantation Tolerance and in the Treatment of Hematologic Malignancies, Symposium sponsored by Mass General Hospital and Harvard Medical School, Boston, MA, 03/18/2001 - 03/19/2001

Graft-versus-Host and Graft-versus-Leukemia Reactions, International Symposium, Munich, Germany, 03/21/2002 - 03/22/2002

National

- Seminar, University of Minnesota, Department of Pediatric Hematology-Oncology and Blood and Marrow Transplant Program, Minneapolis, MN, 1999
- Immunotherapy for Neuroblastoma: Preclinical Studies, Seminar, Roswell Park Cancer Institute, Buffalo, NY, 10/03/2006
- Induction of Immunity to Neuroblastoma Early After Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine, Seminar, University of Nevada at Reno, Reno, NV, 04/03/2007
- Optimizing Immunotherapy for Neuroblastoma Early after Hematopoietic Stem Cell Transplantation - Translational Studies, Seminar, University of Iowa, Iowa City, IA, 08/09/2007
- A Multi-Faceted Approach to Immunotherapy for Neuroblastoma Utilizing Hematopoietic Stem Cell Transplantation, Seminar, University of Minnesota, Department of Pediatric Hematology-Oncology and Blood and Marrow Transplant Program, Minneapolis, MN, 06/09/2008
- Effective Treatment of Established Neuroblastomas using a Multi-Faceted Immunotherapeutic Approach, Immunotherapy in Pediatric Oncology: Progress and Challenges Meeting, National Institutes of Health, 09/09/2008 - 09/10/2008
- Lymphodepletion and PD-1/PD-L1 Blockade as Immunotherapy for Multiple Myeloma, Seminar at Astellas Pharma US, Skokie, IL, 08/06/2012
- Potential for Treating Hematologic Malignancies with Immune Checkpoint Protein Blockade, Roswell Park Memorial Cancer Institute, Buffalo, NY, 05/09/2014

Regional

- Retaining the Beneficial Graft-versus-Leukemia Effect of Allogeneic Bone Marrow Transplantation while Eliminating Graft-versus-Host Disease, Seminar at the University of Health Sciences/The Chicago Medical School, North Chicago, IL, 11/16/1993
- Why is Graft-vs-Host Disease Less Severe than Expected after Posttransplant Cellular Immunotherapy with Donor Cells?, Seminar at the University of Health Sciences/The Chicago Medical School, North Chicago, IL, 11/23/1999
- Induction of Immunity to Neuroblastoma early after Syngeneic Hematopoietic Stem Cell Transplantation using a Novel Mouse Tumor Vaccine, Research Talk at the University of Wisconsin, Madison, Madison, WI, 2006

Local

- How to Prevent Leukemia Relapse Following Allogeneic Bone Marrow Transplantation, Department of Pediatrics Academic Conference, Children's Hospital of Wisconsin, Milwaukee, WI, 09/08/1995
- Treatment for Leukemia Relapse. Following Allogeneic Bone Marrow Transplantation, Department of Pediatrics Grand Rounds, Children's Hospital of Wisconsin, Milwaukee, WI, 05/09/1997
- Immunoregulation and Immunosuppression, Department of Allergy Grand Rounds, Milwaukee, Wisconsin, 04/17/2000
- The Reestablishment of Dominant Peripheral Tolerance after Allogeneic BMT Suppresses Graft-vs-Host Reactivity, Department of Pediatrics Academic Conference, Children's Hospital of Wisconsin, Milwaukee, WI, 02/09/2001
- Development of Novel Cancer Vaccines for Neuroblastoma, Department of Pediatrics Academic Conference, Children's Hospital of Wisconsin, Milwaukee, WI, 03/11/2005
- Development of Novel Cancer Vaccines for Neuroblastoma, MCW Biomedical Resource Personnel Talk, Milwaukee, WI, 04/12/2006
- Vaccines for Neuroblastoma: Working Towards Clinical Translation, Children's Research Institute Seminar, Milwaukee, WI, 08/04/2006
- Immune Evasion by Neuroblastoma Involves the Cytokine Macrophage Migration Inhibitory Factor (MIF), Children's Research Institute Seminar, Milwaukee, WI, 12/21/2007
- Development of Cell-Based Vaccines for Neuroblastoma, Co-Moderator in the 2nd Annual Children's Research Institute Symposium, Milwaukee, WI, 04/15/2008
- Inhibiting the Inhibitors to Improve Immunotherapy for Cancer, Children's Research Institute Seminar, Milwaukee, WI, 02/12/2010
- Targeting the PD-1/PD-L1 Pathway as Immunotherapy for Myeloma, MCW Transplantation Biology and Immunotherapy Cancer Center Program, Milwaukee, WI, 02/2012
- Combined Immune Checkpoint Protein Blockade and Lymphodepletion as Immunotherapy for Hematologic Malignancies, HMT MCW Cancer Center Program, Milwaukee, WI, 04/10/2014

PEER REVIEWED WORKSHOPS/PRESENTATIONS:

International

- Johnson BD, Jing W, Orentas RJ, CD25+ Regulatory T Cell Inhibition Enhances Vaccine-Induced Immunity to Neuroblastoma, International Society for Biological Therapy of Cancer (iSBTc) Annual Meeting, Los Angeles, CA, 10/26/2006 - 10/29/2006
- Zhou Q, Yan X, Orentas RJ, Johnson BD, Tumor-Derived Macrophage Migration Inhibitory Factor (MIF) Inhibits Immune Reactivity to Neuroblastoma In Vivo, International Society for Biological Therapy of Cancer (iSBTc) Annual Meeting - Oral Presentation, Boston, MA, 11/01/2007 - 11/04/2007
- Yan X, Johnson BD, Orentas RJ, A Cell-Based Vaccine for Neuroblastoma Induces VLA-2 (CD49b) on CD8+ T Effector/Memory cells Via CD137L, International Society for Biological Therapy of Cancer (iSBTc) Annual Meeting - Oral Presentation, Boston, MA, 11/01/2007 - 11/04/2007
- Jing W, Yan X Orentas RJ, Johnson BD, A Combination of Hematopoietic Stem Cell Transplantation (HSCT), Adoptive Immunotherapy, and Tumor Vaccination can Eliminate Established Tumor, International Society for Biological Therapy of Cancer (iSBTc) Annual Meeting, Boston, MA, 11/01/2007 - 11/04/2007
- Jing W, Johnson BD, Mechanisms of CD8 Memory Loss to Neuroblastoma after Autologous Hematopoietic Stem Cell Transplantation, International Society for Biological Therapy of Cancer (iSBTc) Annual Meeting, Washington, DC, 10/29/2009 - 10/31/2009
- Kearl T, Johnson BD, Indoleamine 2,3-Dioxygenase Expression by Murine T Cells Following In Vitro Exposure to Tumor Culture Supernatant, International Society for Biological Therapy of Cancer (iSBTc) Annual Meeting, Washington, DC, 10/29/2009 - 10/31/2009
- Hallett WHD, Drobyski WR, Johnson BD, Blockade of the PD-1 Pathway Improves Immunotherapy for Myeloma, International Society for Biological Therapy of Cancer (iSBTc) Annual Meeting, Washington, DC, 10/02/2010 - 10/04/2010

National

- Jing W, Yan X, Orentas RJ, Johnson BD, Syngeneic Neuroblastoma Cells Transiently-Transfected with Plasmid DNA Vectors Encoding a Panel of Immune Stimulatory Molecules Can Induce Anti-Tumor Immunity Early after BMT, Tandem Bone Marrow Transplant Meetings, Honolulu, HI, 02/16/2006 - 02/20/2006
- Orentas R, Yan X, Johnson B, Tumor-Derived Macrophage Migration Inhibitory Factor (MIF) Inhibits Lymphocyte Activation, American Association of Immunologists (AAI) Meeting, Boston, MA, 05/12/2006 - 05/16/2006
- Zhou Q, Orentas RJ, Johnson BD, Determining the Cellular Immune Response to a Subcutaneous Cell-Based Vaccine for Neuroblastoma, American Association of Immunologists (AAI) Meeting, Boston, MA, 05/12/2006 - 05/16/2006
- Orentas R, Zheng J, Kohler ME, Khan J, Johnson B, Discovery of New Immunologic Targets in Neuroblastoma by Vaccination in the Context of Regulatory T Cell Depletion: Immunodominance of the DEK Oncogene, Advances in Neuroblastoma Research Meeting, Los Angeles, CA, 05/17/2006 - 05/20/2006
- Jing W, Orentas RJ, Johnson BD, Vaccine-Induced Anti-Neuroblastoma Immunity Early after HSCT Arises in the Presence of Foxp3+CD25+CD4+ T Cells, American Society of Hematology (ASH) 49th Annual Meeting, Orlando, FL, 12/09/2006 - 12/12/2006
- Orentas RJ, Jing W, Yan X, Johnson BD, Effective Immunotherapy for Neuroblastoma Requires HSCT and T Cell Transfer, Tandem Bone Marrow Transplant Meetings - Oral Presentation, Keystone, CO, 02/18/2007 - 02/12/2007
- Doffek K, Yan X, Sugg SL, Johnson B, Shilyansky J, Targeting Phosphatidylserine Promotes Immunity to Neuroblastoma, American Association for Cancer Research (AACR) Annual Meeting, Los Angeles, CA, 04/14/2007 - 04/18/2007
- Doffek K, Yan X, Sugg SL, Johnson BD, Shilyansky J, Neuroblastoma express phosphatidylserine: mechanism for immune evasion, American Association for Cancer Research (AACR) Annual Meeting, Los Angeles, CA, 04/14/2007 - 04/18/2007
- Gershan J, Yan X, Johnson BD, Immune Suppression is Transferred by Exposure to Supernatant from MIF

Overexpressing Tumor, American Association for Cancer Research (AACR) Special Conference - Tumor Immunology: New Perspectives, Miami, FL, 12/02/2008 - 12/05/2008

Kohler ME, Chen Q, Hallett WH, Johnson BD, Induction of "Stemness" Genes in CD8 T Cells after Vaccination of Tumor-Free Mice with a Cell-Based Vaccine, American Association for Cancer Research (AACR) Special Conference - Tumor Immunology: New Perspectives, Miami, FL, 12/02/2008 - 12/05/2008

Jing W, Johnson BD, Depletion of CD4 T Cells Leads to Increased Tumor Immunity after HSCT Immunotherapy but Results in Loss of Memory, Tandem Bone Marrow Transplant Meetings, Tampa, FL, 02/11/2009 - 02/15/2009

Hallett WHD, Drobyski WR, Johnson BD, B7-H1 Blockade Enhances Immunotherapy for Multiple Myeloma, Autumn Immunology Conference, Chicago, IL, 11/20/2009 - 11/23/2009

Barr K, Johnson BD, Neuroblastoma Suppresses Anti-Tumor Immune Responses at Vaccine Sites, Autumn Immunology Conference, Chicago, IL, 11/19/2010 - 11/22/2010

Palen K, Weber J, Johnson B, Gershan J, Epithelial FVB MMTV-Neu pPrimary Mammary Tumor Cells have Enhanced Tumorigenicity Compared to Fibroblastoid Tumor Cells that Express Mesenchymal and Metastasis-Associated Genes, Tumor Immunology Conference, Miami, FL, 11/2010

Hallett WHD, Drobyski WR, Johnson BD, Inhibiting Immune Suppressive Pathways to Improve Immunotherapy for Myeloma, Tandem Bone Marrow Transplant Meetings - Oral Presentation, Honolulu, HI, 02/17/2011 - 02/21/2011

Barr K, Johnson BD, Examining T Cells at the Vaccine Sites of Tumor-Bearing Hosts Provide Insights to Dysfunctional Tumor Immunity, National Cancer Institute Sponsored Meeting - Cancer Immunology and Immunotherapy: Building on Success, Bethesda, MD, 09/22/2011 - 09/23/2011

Kearl T, Johnson BD, Programmed Death Receptor-1 as a Marker of Tumor-Reactive Cells in a Murine Model of Multiple Myeloma, National Cancer Institute Sponsored Meeting - Cancer Immunology and Immunotherapy: Building on Success, Bethesda, MD, 09/22/2011 - 09/23/2011

Combined Immune Checkpoint Protein Blockade and Lymphodepletion as Immunotherapy for Myeloma, Federation of Clinical Immunology Societies (FOCIS) Annual Meeting - Oral Presentation, Chicago, IL, 06/24/2014 - 06/28/2014

Tumor Immunity Workshop Chair at the Autumn Immunology Conference, 43rd Annual Autumn Immunology Conference - Oral Presentation, Chicago, IL, 11/21/2014 - 11/24/2014

Combined Immune Checkpoint Protein Blockade and Lymphodepletion as Immunotherapy for Myeloma, 43rd Annual Autumn Immunology Conference - Oral Presentation, Chicago, IL, 11/21/2014 - 11/24/2014

Local

Optimizing Adoptive Transfer Immunotherapy for AML Using Bone Marrow-Derived T Cells, Medical College of Wisconsin Cancer Center Retreat - Poster Presentation, Milwaukee, WI, 03/20/2015

COMMITTEE SERVICE:

Medical College of Wisconsin

1994 Member, Task Force on Responsible Conduct of Research, Department of Pediatrics, Medical College of Wisconsin

2003 Member, Research Innovation Task Force, Pediatrics, Medical College of Wisconsin

2003 - Present Member, Cancer Center Grant Review Committee, Medical College of Wisconsin

2004 Member, Research-Salary Support Task Force, Pediatrics, Medical College of Wisconsin

2008 - Present Member, Institutional Animal Care and Use Committee (IACUC), Medical College of Wisconsin

2009 Member, Faculty Evaluation Committee, Hematology-Oncology, Pediatrics, Medical College of Wisconsin

2009 - Present Member, Awards Committee, Graduate School, Medical College of Wisconsin

2010 - Present Chair, Institutional Animal Care and Use Committee (IACUC), Medical College of Wisconsin

2010 - Present Member, Joint Safety Committee, Medical College of Wisconsin

2010 Ad hoc Reviewer, Pilot Innovative Research Grant Applications, Children's Research Institute, Medical College of Wisconsin

MCW TEACHING ACTIVITIES:

Medical Student Education

- 2008 - 2011 Lecturer for the Medical Microbiology Course - Cancer Immunity
- 2009 Proctor for Medical Microbiology Course Small Group Discussions
- 2010 Course Director and Instructor - Tumor Immunology Mini-Course
- 2010 - 2011 Small Group Facilitator for Medical Students in the Physician/Scientist Pathway

Graduate Student Education

- 2001 Instructor for Topics in Microbiology and Immunology graduate class
- 2002 Instructor for Cellular and Molecular Immunology graduate class
- 2004 - 2005 Instructor for Cellular and Molecular Immunology graduate class
- 2009 Instructor for Cellular and Molecular Immunology graduate class

Resident and Fellow Education

- 2006 Lecturer for the Pediatrics, Hem/Onc Fellow Lecture Series
- 2008 Lecturer for the Pediatrics, Hem/Onc Fellow Lecture Series

Continuing Medical Education

- 09/08/1995 Department of Pediatrics Academic Conference Presentation - How to Prevent Leukemia Relapse Following Allogeneic Bone Marrow Transplantation
- 05/09/1997 Department of Pediatrics Grand Rounds Presentation - Treatment for Leukemia Relapse. Following Allogeneic Bone Marrow Transplantation
- 04/17/2000 Department of Allergy Grand Rounds Presentation - Immunoregulation and Immunosuppression
- 02/09/2001 Department of Pediatrics Academic Conference Presentation - The Reestablishment of Dominant Peripheral Tolerance after Allogeneic BMT Suppresses Graft-vs-Host Reactivity
- 03/11/2005 Department of Pediatrics Academic Conference Presentation - Development of Novel Cancer Vaccines for Neuroblastoma
- 04/12/2006 Research Presentation to MCW Biomedical Resource Personnel - Development of Novel Cancer Vaccines for Neuroblastoma
- 08/04/2006 Children's Research Institute Seminar Presentation - Vaccines for Neuroblastoma: Working Towards Clinical Translation
- 12/21/2007 Children's Research Institute Seminar Presentation - Immune Evasion by Neuroblastoma Involves the Cytokine Macrophage Migration Inhibitory Factor (MIF)
- 04/15/2008 Participant and Co-Moderator in the 2nd Annual Children's Research Institute Symposium Presentation - Development of Cell-Based Vaccines for Neuroblastoma
- 02/12/2010 Children's Research Institute Seminar Presentation - Inhibiting the Inhibitors to Improve Immunotherapy for Cancer

MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:

Medical Students

- 2000 Nabil Dagher, Summer Student Mentor, Medical College of Wisconsin
- 2003 Heidi Zujewski, Summer Student Mentor, Medical College of Wisconsin
- 2004 Steven Summer, Summer Student Mentor, Medical College of Wisconsin
- 2005 Andy Thill, Summer Student Mentor, Medical College of Wisconsin
- 2006 Daniel Butz, Summer Student Mentor, Medical College of Wisconsin
- 2007 Kristin Mueller, Summer Student Mentor, Medical College of Wisconsin
- 2008 Melissa Holmes, Summer Student Mentor, Medical College of Wisconsin
- 2011 Kasper Warrick, Summer Student Mentor, Medical College of Wisconsin
- 2012 David Horn, Summer Student Mentor, Medical College of Wisconsin

Graduate Students

PhD Committees

- 2005 - 2009 M. Eric Kohler, Medical College of Wisconsin
- 2009 - Present Steven Leonardo, Medical College of Wisconsin
- 2010 - Present Mika Nagaoka, Medical College of Wisconsin

2011 - Present Ishan Roy, Medical College of Wisconsin
2013 - Present Jonathan Ebben, Medical College of Wisconsin

PhD Students Advised

09/2008 - Present Tyce Kearl, Medical College of Wisconsin
06/2009 - Present Kristen Barr, Medical College of Wisconsin

Postdoctoral Researchers

2001 - 2003 Guliang Xia, MD, PhD, Postdoctoral Mentor, Medical College of Wisconsin
2002 - 2003 Ou Cao, MD, PhD, Postdoctoral Mentor, Medical College of Wisconsin
2003 - 2009 Xiaocai Yan, MD, PhD, Postdoctoral Mentor, Medical College of Wisconsin
2004 - 2007 Qiang Zhou, PhD, Postdoctoral Mentor, Medical College of Wisconsin
2004 - 2010 Weiqing Jing, MD, Postdoctoral Mentor, Medical College of Wisconsin
2008 - 2011 William Hallett, PhD, Postdoctoral Mentor, Medical College of Wisconsin

Clinical/Research Fellows

2002 - 2004 Meghan Browning, MD, Research Mentor, Medical College of Wisconsin
2009 - Present Hemalatha Rangarajan, MD, Scholarship Oversight Committee, Medical College of Wisconsin
2010 - 2013 Chelsea Collins, MD, Scholarship Oversight Committee, Medical College of Wisconsin
2011 - 2012 Dominic Co, Scholarship Oversight Committee, Medical College of Wisconsin

Faculty

2008 - Present Jill Gershan, PhD, Mentorship Committee, Medical College of Wisconsin
2009 - Present Qizhen Shi, MD, PhD, Mentorship Committee, Medical College of Wisconsin
2013 - Present Haris Vikis, Mentorship Committee, Medical College of Wisconsin
2013 - Present Xiao Chen, Mentorship Committee, Medical College of Wisconsin

COMMUNITY SERVICE ACTIVITIES:

Big Brothers and Sisters of Washington County - Big Brother (1992-2002; 2007-Present)

BIBLIOGRAPHY

Refereed Journal Publications/Original Papers

1. Baum LL, **Johnson B**, Berman S, Graham D, Mold C. C-reactive protein is involved in natural killer cell-mediated lysis but does not mediate effector-target cell recognition. *Immunology*. 1987 May;61(1):93-9. PMID: PMC1453307
2. **Johnson BD**, Kim YB. Characterization of a monoclonal antibody enhancing porcine natural killer cell activity (PNK-E). *Cell Immunol*. 1990 Jan;125(1):107-19.
3. **Johnson BD**, Wierda WG, Kim YB. Further characterization of PNK-E: a monoclonal antibody enhancing porcine natural killer cell activity. *Cell Immunol*. 1991 May;134(2):378-89.
4. **Johnson BD**, Truitt RL. A decrease in graft-vs.-host disease without loss of graft-vs.-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo. *Transplantation*. 1992 Jul;54(1):104-12.
5. Wierda WG, **Johnson BD**, Dato ME, Kim YB. Two distinct porcine natural killer lytic trigger molecules as PNK-E/G7 molecular complex. *Cell Immunol*. 1993 Feb;146(2):270-83.
6. **Johnson BD**, Drobyski WR, Truitt RL. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. *Bone Marrow Transplant*. 1993 Apr;11(4):329-36.
7. Wierda WG, **Johnson BD**, Dato ME, Kim YB. Induction of porcine granulocyte-mediated tumor cytotoxicity by two distinct monoclonal antibodies against lytic trigger molecules (PNK-E/G7). *J Immunol*. 1993 Dec 15;151(12):7117-27.
8. **Johnson BD**, Truitt RL. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. *Blood*. 1995 Jun 01;85(11):3302-12.
9. Truitt RL, **Johnson BD**. Principles of graft-vs.-leukemia reactivity. *Biol Blood Marrow Transplant*. 1995

Dec;1(2):61-8.

10. **Johnson BD**, McCabe C, Hanke CA, Truitt RL. Use of anti-CD3 epsilon F(ab')₂ fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation. *J Immunol*. 1995 May 15;154(10):5542-54.
11. **Johnson BD**, Hanke CA, Truitt RL. The graft-versus-leukemia effect of post-transplant donor leukocyte infusion. *Leuk Lymphoma*. 1996 Sep;23(1-2):1-9.
12. **Johnson BD**, Hanke CA, Becker EE, Truitt RL. Sc1(+)/Mac1(+) nitric oxide-producing cells in the spleens of recipients early following bone marrow transplant suppress T cell responses in vitro. *Cell Immunol*. 1998 Nov 01;189(2):149-59.
13. **Johnson BD**, Becker EE, Truitt RL. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. *Biol Blood Marrow Transplant*. 1999;5(3):123-32.
14. Truitt RL, **Johnson BD**, Hanke C, Talib S, Hearst JE. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation. *J Immunol*. 1999 Nov 01;163(9):5145-56.
15. **Johnson BD**, Becker EE, LaBelle JL, Truitt RL. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy. *J Immunol*. 1999 Dec 15;163(12):6479-87.
16. **Johnson BD**, Kurup VP, Sussman GL, Arif SA, Kelly KJ, Beezhold DH, Fink JN. Purified and recombinant latex proteins stimulate peripheral blood lymphocytes of latex allergic patients. *Int Arch Allergy Immunol*. 1999 Dec;120(4):270-9.
17. Banerjee B, Kurup VP, Greenberger PA, **Johnson BD**, Fink JN. Cloning and expression of *Aspergillus fumigatus* allergen Asp f 16 mediating both humoral and cell-mediated immunity in allergic bronchopulmonary aspergillosis (ABPA). *Clin Exp Allergy*. 2001 May;31(5):761-70.
18. Rathore VB, **Johnson B**, Fink JN, Kelly KJ, Greenberger PA, Kurup VP. T cell proliferation and cytokine secretion to T cell epitopes of Asp f 2 in ABPA patients. *Clin Immunol*. 2001 Aug;100(2):228-35.
19. Orentas RJ, Schauer D, Bin Q, **Johnson BD**. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. *Cell Immunol*. 2001 Oct 10;213(1):4-13.
20. **Johnson BD**, Dagher N, Stankowski WC, Hanke CA, Truitt RL. Donor natural killer (NK1.1+) cells do not play a role in the suppression of GVHD or in the mediation of GVL reactions after DLI. *Biol Blood Marrow Transplant*. 2001;7(11):589-95.
21. Bin Q, **Johnson BD**, Schauer DW, Casper JT, Orentas RJ. Production of macrophage migration inhibitory factor by human and murine neuroblastoma. *Tumour Biol*. 2002;23(3):123-9.
22. **Johnson BD**, Taylor PA, Stankowski MC, Talib S, Hearst JE, Blazar BR. Photochemical treatment of donor lymphocytes inhibited their ability to facilitate donor engraftment or increase donor chimerism after nonmyeloablative conditioning or establishment of mixed chimerism. *Biol Blood Marrow Transplant*. 2002;8(11):581-7.
23. **Johnson BD**, Konkol MC, Truitt RL. CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. *Biol Blood Marrow Transplant*. 2002;8(10):525-35.
24. **Johnson BD**, Yan X, Schauer DW, Orentas RJ. Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule. *Cell Immunol*. 2003 Mar;222(1):15-26.
25. Wilcox DA, Shi Q, Nurden P, Haberichter SL, Rosenberg JB, **Johnson BD**, Nurden AT, White GC 2nd, Montgomery RR. Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. *J Thromb Haemost*. 2003 Dec;1(12):2477-89.
26. Browning MB, Woodliff JE, Konkol MC, Pati NT, Ghosh S, Truitt RL, **Johnson BD**. The T cell activation marker CD150 can be used to identify alloantigen-activated CD4(+)25+ regulatory T cells. *Cell Immunol*. 2004 Feb;227(2):129-39.
27. Rosenblum MD, Olasz E, Woodliff JE, **Johnson BD**, Konkol MC, Gerber KA, Orentas RJ, Sandford G, Truitt RL. CD200 is a novel p53-target gene involved in apoptosis-associated immune tolerance. *Blood*. 2004 Apr 01;103(7):2691-8.
28. Yan X, **Johnson BD**, Orentas RJ. Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo. *Immunology*. 2004 May;112(1):105-16. PMID: PMC1782467
29. Xia G, Kovoichich M, Truitt RL, **Johnson BD**. Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease. *Biol Blood Marrow Transplant*. 2004 Nov;10(11):748-60.

30. Gershan JA, **Johnson BD**, Weber J, Schauer DW, Natalia N, Behnke S, Burns K, Maloney KW, Warwick AB, Orentas RJ. Immediate transfection of patient-derived leukemia: a novel source for generating cell-based vaccines. *Genet Vaccines Ther.* 2005 Jun 21;3(1):4. PMID: PMC1182385
31. **Johnson BD**, Gershan JA, Natalia N, Zujewski H, Weber JJ, Yan X, Orentas RJ. Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice. *J Immunother.* 2005;28(5):449-60.
32. Fang J, Hodivala-Dilke K, **Johnson BD**, Du LM, Hynes RO, White GC 2nd, Wilcox DA. Therapeutic expression of the platelet-specific integrin, alphaIIb beta3, in a murine model for Glanzmann thrombasthenia. *Blood.* 2005 Oct 15;106(8):2671-9. PMID: PMC1895311
33. Barrios CS, **Johnson BD**, D Henderson J Jr, Fink JN, Kelly KJ, Kurup VP. The costimulatory molecules CD80, CD86 and OX40L are up-regulated in *Aspergillus fumigatus* sensitized mice. *Clin Exp Immunol.* 2005 Nov;142(2):242-50. PMID: PMC1809515
34. Yan X, Orentas RJ, **Johnson BD**. Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation. *Cytokine.* 2006 Feb 21;33(4):188-98. PMID: PMC2018658
35. Xia G, Truitt RL, **Johnson BD**. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. *Biol Blood Marrow Transplant.* 2006 Apr;12(4):397-407.
36. Shi Q, Wilcox DA, Fahs SA, Fang J, **Johnson BD**, DU LM, Desai D, Montgomery RR. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. *J Thromb Haemost.* 2007 Feb;5(2):352-61.
37. Zhou Q, **Johnson BD**, Orentas RJ. Cellular immune response to an engineered cell-based tumor vaccine at the vaccination site. *Cell Immunol.* 2007 Feb;245(2):91-102. PMID: PMC1949498
38. **Johnson BD**, Jing W, Orentas RJ. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. *J Immunother.* 2007;30(2):203-14.
39. Jing W, Orentas RJ, **Johnson BD**. Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine. *Biol Blood Marrow Transplant.* 2007 Mar;13(3):277-92. PMID: PMC1852542
40. Chen X, Vodanovic-Jankovic S, **Johnson B**, Keller M, Komorowski R, Drobyski WR. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. *Blood.* 2007 Nov 15;110(10):3804-13. PMID: PMC2077325
41. Kurup VP, Barrios CS, Raju R, **Johnson BD**, Levy MB, Fink JN. Immune response modulation by curcumin in a latex allergy model. *Clin Mol Allergy.* 2007 Jan 25;5:1. PMID: PMC1796894
42. Keever-Taylor CA, Browning MB, **Johnson BD**, Truitt RL, Bredeson CN, Behn B, Tsao A. Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. *Cytotherapy.* 2007;9(2):144-57.
43. Zheng J, Kohler ME, Chen Q, Weber J, Khan J, **Johnson BD**, Orentas RJ. Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen. *BMC Immunol.* 2007 Mar 30;8:4. PMID: PMC1852119
44. Zhou Q, Yan X, Gershan J, Orentas RJ, **Johnson BD**. Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo. *J Immunol.* 2008 Aug 01;181(3):1877-86. PMID: PMC3804024
45. Yan X, **Johnson BD**, Orentas RJ. Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L. *J Immunol.* 2008 Oct 01;181(7):4621-31. PMID: PMC2975591
46. Jing W, Gershan JA, **Johnson BD**. Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory. *Blood.* 2009 Apr 30;113(18):4449-57. PMID: PMC2676098
47. **Johnson B**, Drobyski W, Blazar B, Korngold R. Robert Truitt tribute. *Biol Blood Marrow Transplant.* 2010 Jan;16(1):143-4.
48. Cludts S, Decaestecker C, **Johnson B**, Lechien J, Leroy X, Kindt N, Kaltner H, André S, Gabius HJ, Saussez S. Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma. *Anticancer Res.* 2010 Sep;30(9):3313-9.
49. Kohler ME, **Johnson BD**, Palen K, Chen QR, Khan J, Orentas RJ. Tumor antigen analysis in neuroblastoma by serological interrogation of bioinformatic data. *Cancer Sci.* 2010 Nov;101(11):2316-24. PMID: PMC3103783

50. Kohler ME, Hallett WH, Chen QR, Khan J, **Johnson BD**, Orentas RJ. Early expression of stem cell-associated genes within the CD8 compartment after treatment with a tumor vaccine. *Cell Immunol.* 2010;265(1):65-73. PMID: PMC2935508
51. Jing W, Yan X, Hallett WH, Gershan JA, **Johnson BD**. Depletion of CD25⁺ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma. *Blood.* 2011 Jun 23;117(25):6952-62. PMID: PMC3128485
52. Hallett WH, Jing W, Drobyski WR, **Johnson BD**. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. *Biol Blood Marrow Transplant.* 2011 Aug;17(8):1133-45.
53. Palen KA, Jing W, Weber JJ, Tilkens SB, Chan AM, **Johnson BD**, Gershan JA. Separation and Characterization of Epithelial and Mesenchymal-like Murine Mammary Tumor Cells Reveals Epithelial Cell Differentiation Plasticity and Enhanced Tumorigenicity of Epithelial-enriched Tumor Cells. *Cancer Microenviron.* 2013 Apr;6(1):79-89. PMID: PMC3601216
54. Yan X, Doffek K, Yin C, Krein M, Phillips M, Sugg SL, **Johnson B**, Shilyansky J. Annexin-V promotes anti-tumor immunity and inhibits neuroblastoma growth in vivo. *Cancer Immunol Immunother.* 2012 Nov;61(11):1917-27. PMID: PMC11029734
55. Barr KM, Jing W, Hallett WH, Gershan JA, **Johnson BD**; Examining T Cells at Vaccine Sites of Tumor-Bearing Hosts Provides Insights to Dysfunctional T Cell Immunity, *J Immunother.* 2013 Jan;36(1):41-51
56. Zhang G, Chen F, Cao Y, **Johnson Bl**, and See WA: HMGB1 release by urothelial carcinoma cells is required for the in vivo antitumor response to Bacillus Calmette-Guérin. *Journal of Urology*, 2013 Apr 189(4):1541-6
57. Kindt N, Preillon J, Kaltner H, Gabius HJ, Chevalier D, **Johnson BD.**, Megalizzi V, Decaestecker C, Laurent G, and Saussez S: J Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies. *J of Cancer Res and Clin Oncol.*, 2013 May;139(5):727-37
58. Kearl TJ, Jing W J, Gershan JA, **Johnson BD**; Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma:*J Immunol* 2013 Jun 1;190(11):5620-8
59. Jing W, Gershan JA, Weber J, Tlomak D, McOlash L, Sabatos-Peyton C, **Johnson BD**. Combined Immune Checkpoint Protein Blockade and Low Dose Whole Body Irradiation as Immunotherapy for Myeloma. *J Immunother Cancer.* 2015 Jan 20;3(1):2.
60. Gershan JA, Barr KM, Weber JJ, Jing W, **Johnson BD**. Immune modulating effects of cyclophosphamide and treatment with tumor lysate/CpG synergize to eliminate murine neuroblastoma. *J Immunother Cancer.* 2015 Jun 16;3:24. PMID: PMC4469315

Books, Chapters, and Reviews

1. Truitt RL JB. Graft-versus-host disease and the graft-versus-leukemia effect: Lessons from allogeneic bone marrow transplantation. In: T. Spitzer and A. Mazumder, ed. *Immunotherapy and bone marrow transplantation*. Armonk, NY: Futura Publishing; 1995.
2. Truitt RL, **Johnson BD**, McCabe C, Weiler MB. Graft-versus-leukemia. In: JLM Ferrara and S Burnakoff, ed. *Graft-vs-host disease: Immunology, pathophysiology and treatment*. Second ed. New York: Marcel Dekker; 1997.
3. Yan X, Orentas RJ, **Johnson BD**. Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation. *Cytokine.* 2006 Feb 21;33(4):188-98. PMID: PMC2018658
4. Orentas RJ, Kohler ME, **Johnson BD**. Suppression of anti-cancer immunity by regulatory T cells: back to the future. *Semin Cancer Biol.* 2006 Apr;16(2):137-49.
5. Truitt RL, Horowitz MM, Atasoylu AA, Drobyski WD, **Johnson BD**, LeFever AV. Graft-versus-Leukemia Effect of Allogeneic Bone Marrow Transplantation: Clinical and Experimental Aspects of Late Leukemia Relapse. IN: *Cellular Immune Mechanisms and Tumor Dormancy* (THM Stewart, ed.), CRC Press, Inc., Boca Raton, p 111, 1992.
6. Jing W, **Johnson BD**. Tumor Vaccination after Autologous HSCT: What has been Learned from Experimental Models? IN: *Cancer Vaccines and Tumor Immunity* (R. Orentas, B. Johnson and J. Hodge, eds.), John Wiley & Sons, Inc., Hoboken, NJ, pp. 205-215, 2008.
7. Xia G, He J, Leventhal JR. Ex vivo-expanded natural CD4⁺CD25⁺ regulatory T cells synergize with host T-cell depletion to promote long-term survival of allografts. *Am J Transplant.* 2008 Feb;8(2):298-306.
8. Truitt RL, Korngold R, **Johnson BD**, Townsend R, Blazar RB. Experimental Animal Models in the Study of GVL Reactions. IN: *The Graft Versus Leukemia Effect In Allogeneic Stem Cell Transplantation*, (J.

- Barrett and Y. Jiang, eds.), Marcel Dekker, New York, 2000, p. 39.
9. Kearnl TJ, Jing W, Gershan JA, **Johnson BD**. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. *J Immunol*. 2013 Jun 01;190(11):5620-8. PMID: PMC3891840
 10. Kearnl TJ, Jing W, Gershan JA, **Johnson BD** Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion to Treat Myeloma. *J Immunol*. 2013 Apr 24
 11. Truitt RL, Korngold R, **Johnson BD**, Townsend R, Blazar RB. Experimental Animal Models in the Study of GVL Reactions. IN: *The Graft Versus Leukemia Effect In Allogeneic Stem Cell Transplantation*, (J. Barrett and Y. Jiang, eds.), Marcel Dekker, New York, 2000,
 12. Xia G, Zhang Z, **Johnson BD**: Prevention of Heart Allograft Rejection by Immunotherapy with Ex Vivo-Expanded Foxp3+CD4 +CD25+ Natural Regulatory T Cells. IN: *Heart Transplantation: Indications and Contraindications, Procedures and Complications* (C.T. Fleming ed.), Nova Science Publishers, Inc., Hauppauge, NY, 2009.
 13. Gershan J, Chan A, Chrzanowska-Wodnicka M, **Johnson B**, Miao Q, Ramchandran R.: Endothelial and Accessory Cell Interactions in Neuroblastoma Tumor Microenvironment. IN: *Research Directions in Tumor Angiogenesis* (J. Chai ed.), Intech Open Access, ISBN 978-953-51-0963-1, 2013.
 14. Barr KM, Gershan JA, **Johnson BD**: Hematopoietic Stem Cell Transplantation and Lymphodepletion for the Treatment of Cancer. IN: *Cancer Immunology: Translational Medicine from Bench to Bedside* (N. Rezaei ed.), Springer, submitted for publication.
 15. Jing W, Gershan JA, Weber J, Tlomak D, McOlash L, Sabatos-Peyton C, **Johnson BD**. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. *J Immunother Cancer*. 2015;3(1):2. PMID: PMC4302511
 16. Palen KA, Jing W, Weber JJ, Tilkens SB, Chan AM, **Johnson BD**, Gershan JA. Erratum to: Separation and Characterization of Epithelial and Mesenchymal-like Murine Mammary Tumor Cells Reveals Epithelial Cell Differentiation Plasticity and Enhanced Tumorigenicity of Epithelial-enriched Tumor Cells. *Cancer Microenviron*. 2016 Apr;9(1):75. PMID: PMC4842184
 17. Cheng G, Zielonka J, Ouari O, Lopez M, McAllister D, Boyle K, Barrios CS, Weber JJ, **Johnson BD**, Hardy M, Dwinell MB, Kalyanaraman B. Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells. *Cancer Res*. 2016 Jul 01;76(13):3904-15. PMID: PMC4930686
 18. Palen K, Weber J, Dwinell MB, **Johnson BD**, Ramchandran R, Gershan JA. E-cadherin re-expression shows in vivo evidence for mesenchymal to epithelial transition in clonal metastatic breast tumor cells. *Oncotarget*. 2016 Jul 12;7(28):43363-43375. PMID: PMC5190029
 19. Riese MJ, Moon EK, **Johnson BD**, Albelda SM. Diacylglycerol Kinases (DGKs): Novel Targets for Improving T Cell Activity in Cancer. *Front Cell Dev Biol*. 2016;4:108. PMID: PMC5065962
 20. Xin G, Schauder DM, Jing W, Jiang A, Joshi NS, **Johnson B**, Cui W. A Pathogen Boosted Adoptive Cell Transfer Immunotherapy to Treat Solid Tumors, *PNAS*, Epub ahead of print. PMID: 28069963.
 21. Jing W, Gershan JA, Blitzer GC, Palen K, Weber J, McOlash L, Riese M, **Johnson BD**. Adoptive cell therapy using PD-1^{hi} myeloma-reactive T cells eliminates established myeloma in mice. *J Immunother Cancer*. 2017;5:51. PMID: PMC5477110
 22. Jing W, Gershan JA, Holzhauser S, Weber J, Palen K, McOlash L, Pulakanti K, Wesley E, Rao S, **Johnson BD**, Riese MJ. T Cells Deficient in Diacylglycerol Kinase ? Are Resistant to PD-1 Inhibition and Help Create Persistent Host Immunity to Leukemia. *Cancer Res*. 2017 Oct 15;77(20):5676-5686.
 23. Palen K, Thakar M, **Johnson BD**, Gershan JA. Bone Marrow-derived CD8⁺ T Cells From Pediatric Leukemia Patients Express PD1 and Expand Ex Vivo Following Induction Chemotherapy. *J Pediatr Hematol Oncol*. 2019 Nov;41(8):648-652. PMID: PMC6855330
 24. Wesley EM, Xin G, McAllister D, Malarkannan S, Newman DK, Dwinell MB, Cui W, **Johnson BD**, Riese MJ. Diacylglycerol kinase ? (DGK?) and Casitas b-lineage proto-oncogene b-deficient mice have similar functional outcomes in T cells but DGK?-deficient mice have increased T cell activation and tumor clearance. *Immunohorizons*. 2018 Apr 01;2(4):107-118. PMID: PMC6048965
 25. Newman DK, Fu G, McOlash L, Schauder D, Newman PJ, Cui W, Rao S, **Johnson BD**, Gershan JA, Riese MJ. Frontline Science: PECAM-1 (CD31) expression in naïve and memory, but not acutely activated, CD8⁺ T cells. *J Leukoc Biol*. 2018 Nov;104(5):883-893. PMID: PMC6195461
 26. Tsai S, McOlash L, Jia S, Zhang J, Simpson P, Kaldunski ML, Aldakkak M, Grewal J, Palen K, Dwinell MB, **Johnson BD**, Mackinnon A, Hessner MJ, Gershan JA. A Serum-Induced Transcriptome and Serum Cytokine Signature Obtained at Diagnosis Correlates with the Development of Early Pancreatic Ductal Adenocarcinoma Metastasis. *Cancer Epidemiol Biomarkers Prev*. 2019 Apr;28(4):680-689.

PMCID: PMC6545232

27. Jing W, McAllister D, Vonderhaar EP, Palen K, Riese MJ, Gershan J, **Johnson BD**, Dwinell MB. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. *J Immunother Cancer*. 2019 Apr 29;7(1):115. PMCID: PMC6489306
28. Truitt RL, **Johnson BD**, Korngold R, Townsend R, Blazar BR. Experimental animal models in the study of GVL reactions Allogeneic Immunotherapy for Malignant Diseases. 1 January 2000:39-74.
29. Orentas R, Hodge JW, **Johnson BD**. Cancer Vaccines and Tumor Immunity *Cancer Vaccines and Tumor Immunity*. 1 March 2007:1-334.
30. Truitt RL, Horowitz MM, Atasoylu AA, Drobyski WR, **Johnson BD**, LeFever AV. Graft-versus-leukemia effect of allogeneic bone marrow transplantation: Clinical and experimental aspects of late leukemia relapse *Cellular Immune Mechanisms and Tumor Dormancy*. 1 January 2017:111-132.
31. Jing W, Chen J, Cai Y, Chen Y, Schroeder JA, **Johnson BD**, Cui W, Shi Q. Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice. *Blood Adv*. 2019 Oct 22;3(20):3099-3110. PMCID: PMC6849959
32. Badar T, Dhakal B, Szabo A, Padmanabhan A, **Johnson BD**, Heidtke S, Esselmann J, Chhabra S, Hamadani M, Hari P, D'Souza A. An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. *J Clin Apher*. 2019 Dec;34(6):686-691. PMCID: PMC6957224
33. D'Souza A, Hari P, Pasquini M, Braun T, **Johnson B**, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A. A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. *Biol Blood Marrow Transplant*. 2019 Aug;25(8):1492-1497.
34. Shah NN, Maatman T, Hari P, **Johnson B**. Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. *Front Oncol*. 2019;9:146. PMCID: PMC6423158
35. Pan J, Zhang Q, Palen K, Wang L, Qiao L, **Johnson B**, Sei S, Shoemaker RH, Lubet RA, Wang Y, You M. Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator *EBioMedicine*. 2019.
36. Tsai S, McOlash L, Palen K, **Johnson B**, Duris C, Yang Q, Dwinell MB, Hunt B, Evans DB, Gershan J, James MA. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. *BMC Cancer*. 2018 Mar 27;18(1):335. PMCID: PMC5870823
37. Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, **Johnson B**, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. *Haematologica*. 2018 Apr;103(4):717-727. PMCID: PMC5865423
38. Xin G, Schauder DM, Jing W, Jiang A, Joshi NS, **Johnson B**, Cui W. Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors. *Proc Natl Acad Sci U S A*. 2017 Jan 24;114(4):740-745. PMCID: PMC5278465
39. Barr KM, Gershan JA, **Johnson BD**. Hematopoietic stem cell transplantation and lymphodepletion for the treatment of cancer *Cancer Immunology: Bench to Bedside Immunotherapy of Cancers*. 1 January 2015:189-201.
40. Xia G, Zhang Z, **Johnson BD**. Prevention of heart allograft rejection by immunotherapy with ex vivo-expanded Foxp3⁺CD4⁺CD25⁺ natural regulatory T cells *Heart Transplantation: Indications and Contraindications, Procedures and Complications*. January 2011:25-49.
41. Hallett W, **Johnson B**. Exploiting arginase to prevent GVHD *Blood*. 16 December 2010;116(25):5440-5441.
42. Orentas RJ, **Johnson B**, Hodge J. Cancer Vaccines: Progress and Promise *Cancer Vaccines and Tumor Immunity*. 1 March 2007:1-11.
43. Jing W, **Johnson BD**. Tumor Vaccination after Autologous HSCT: What has been Learned from Experimental Models *Cancer Vaccines and Tumor Immunity*. 1 March 2007:205-215.
44. Xia G, Zhang Z, **Johnson BD**. Prevention of heart allograft rejection by immunotherapy with ex vivo-expanded Foxp3⁺CD4⁺CD25⁺ natural regulatory T cells *Heart Transplantation: Indications and Contradictions, Procedures and Complications*. 1 January 2009:25-49.
45. Shah NN, **Johnson BD**, Fenske TS, Raj RV, Hari P. Intrathecal chemotherapy for management of steroid-

- refractory CAR T-cell-associated neurotoxicity syndrome. *Blood Adv.* 2020 May 26;4(10):2119-2122. PMID: PMC7252557
46. Badar T, **Johnson BD**, Hamadani M. Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. *Bone Marrow Transplant.* 2021 Mar;56(3):683-685.
 47. Chhabra S, Thapa B, Szabo A, Konings S, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, **Johnson BD**, Hari PN, Hamadani M. Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. *Biol Blood Marrow Transplant.* 2020 Nov;26(11):2011-2017.
 48. Shah NN, Jerkins JH, **Johnson BD**, Hari P. Treatment-Emergent Tumor Lysis Syndrome With PI3K γ Inhibition After CAR T-Cell Therapy for Chronic Lymphocytic Leukemia. *JCO Oncol Pract.* 2020 Sep;16(9):613-614.
 49. Shah NN, **Johnson BD**, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropuli B, Orentas R, Hari P. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase I dose escalation and expansion trial. *Nat Med.* 2020 Oct;26(10):1569-1575.
 50. Lenarczyk M, Laiakis EC, Mattson DL, **Johnson BD**, Kronenberg A, North PE, Komorowski R, Mäder M, Baker JE. Irradiation of the kidneys causes pathologic remodeling in the nontargeted heart: A role for the immune system. *FASEB Bioadv.* 2020 Dec;2(12):705-719. PMID: PMC7734425
 51. Vonderhaar EP, Barnekow NS, McAllister D, McOlash L, Eid MA, Riese MJ, Tarakanova VL, **Johnson BD**, Dwinell MB. STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer. *Cell Mol Gastroenterol Hepatol.* 2021;12(1):41-58. PMID: PMC8081932
 52. Zurko J, Chaney K, Astle JM, **Johnson BD**, Hari P, Shah NN. PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response. *Haematologica.* 2021 Oct 01;106(10):2788-2790. PMID: PMC8485669
 53. Miller MS, Allen PJ, Brown PH, Chan AT, Clapper ML, Dashwood RH, Demehri S, Disis ML, DuBois RN, Glynn RJ, Kensler TW, Khan SA, **Johnson BD**, Liby KT, Lipkin SM, Mallery SR, Meuillet EJ, Roden RBS, Schoen RE, Sharp ZD, Shirwan H, Siegfried JM, Rao CV, You M, Vilar E, Szabo E, Mohammed A. Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting. *J Cancer Prev.* 2021 Mar 30;26(1):71-82. PMID: PMC8020174
 54. AbuEid M, McAllister DM, McOlash L, Harwig MC, Cheng G, Drouillard D, Boyle KA, Hardy M, Zielonka J, **Johnson BD**, Hill RB, Kalyanaraman B, Dwinell MB. Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression. *iScience.* 25 June 2021;24(6).
 55. Palen K, Zurko J, **Johnson BD**, Hari P, Shah NN. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model? *Cytotherapy.* 2021 Nov;23(11):985-990.
 56. Pan J, Chen Y, Zhang Q, Khatun A, Palen K, Xin G, Wang L, Yang C, **Johnson BD**, Myers CR, Sei S, Shoemaker RH, Lubet RA, Wang Y, Cui W, You M. Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA. *Commun Biol.* 2021 Jul 23;4(1):906. PMID: PMC8302676
 57. AbuEid M, McAllister DM, McOlash L, Harwig MC, Cheng G, Drouillard D, Boyle KA, Hardy M, Zielonka J, **Johnson BD**, Hill RB, Kalyanaraman B, Dwinell MB. Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression. *iScience.* 2021 Jun 25;24(6):102653. PMID: PMC8220235
 58. Zurko JC, **Johnson BD**, Aschenbrenner E, Fenske TS, Hamadani M, Hari P, Shah NN. Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome. *JAMA Oncol.* 2022 May 01;8(5):773-775. PMID: PMC8914887
 59. Huang M, Xiong D, Pan J, Zhang Q, Wang Y, Myers CR, **Johnson BD**, Hardy M, Kalyanaraman B, You M. Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria-Targeted Atovaquone. *Adv Sci (Weinh).* 2022 Apr;9(12):e2101267. PMID: PMC9036031
 60. Mohammed A, Dashwood RH, Dickinson S, Disis ML, Jaffee EM, **Johnson BD**, Khleif SN, Pollak MN, Schlom J, Shoemaker RH, Stanton SE, Wondrak GT, You M, Zhu H, Miller MS. Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report. *J Cancer Prev.* 2021 Dec 30;26(4):309-317. PMID: PMC8749317
 61. Taylor MR, Hillard CJ, Drobyski WR, Szabo A, **Johnson BD**, Zhu F, Raison CL, Cole SW, Knight JM. The

- effect of tocilizumab on patient reported outcomes and inflammatory biomarkers in hematopoietic cell transplantation. *Brain Behav Immun Health*. 2022 Aug;23:100480. PMID: PMC9213229
62. Zurko JC, Xu H, Chaney K, Schneider D, Szabo A, Hari P, **Johnson BD**, Shah NN. Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies. *Cytotherapy*. 2022 Aug;24(8):767-773.
 63. Chu Y, Talano JA, Baxter-Lowe LA, Verbsky JW, Morris E, Mahanti H, Ayello J, Keever-Taylor C, **Johnson B**, Weinberg RS, Shi Q, Moore TB, Fabricatore S, Grossman B, van de Ven C, Shenoy S, Cairo MS. Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease. *Front Immunol*. 2022;13:1055497. PMID: PMC9780682
 64. Zurko JC, Fenske TS, **Johnson BD**, Bucklan D, Szabo A, Xu H, Chaney K, Hamadani M, Hari P, Shah NN. Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells. *Am J Hematol*. 2022 Dec;97(12):1580-1588.
 65. Pan J, Xiong D, Zhang Q, Palen K, Shoemaker RH, **Johnson B**, Sei S, Wang Y, You M. Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention. *Front Immunol*. 2023;14:1036563. PMID: PMC9982083
 66. Knight JM, Hackett E, Szabo A, Wu R, Sauber G, **Johnson B**, Cusatis RN, Aughey E, Cole SW, Hillard CJ, Shah NN. Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes. *Haematologica*. 2023 Feb 01;108(2):588-593. PMID: PMC9890001
 67. Barr KM, Khoshbin AP, Gershan JA, **Johnson BD**. Hematopoietic stem cell transplantation and lymphodepletion for the treatment of cancer *Cancer Immunology: Bench to Bedside Immunotherapy of Cancers, Second Edition*. 24 September 2020:143-156.
 68. Chu Y, Milner J, Lamb M, Maryamchik E, Rigot O, Ayello J, Harrison L, Shaw R, Behbehani GK, Mardis ER, Miller K, Prakruthi Rao Venkata L, Chang H, Lee D, Rosenthal E, Kadauke S, Bunin N, Talano JA, **Johnson B**, Wang Y, Cairo MS. Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes. *J Infect Dis*. 2023 Mar 28;227(6):788-799.
 69. Leahy AB, Li Y, Talano JA, Elgarten CW, Seif AE, Wang Y, **Johnson B**, Monos DS, Kadauke S, Olson TS, Freedman J, Wray L, Grupp SA, Bunin N. Unrelated donor T cell- and B cell-depleted HSCT for the treatment of pediatric acute leukemia. *Blood Adv*. 2022 Feb 22;6(4):1175-1185. PMID: PMC8864664
 70. Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Somaiya Dutt P, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, **Johnson B**, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D. Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. *Clin Cancer Res*. 2023 Dec 01;29(23):4784-4796. PMID: PMC10690096
 71. Eapen M, Malec LM, Armant MA, **Johnson BD**, Shi Q, Xu H, Du LM, Jerkins JH, Duffy LJ, Bushman FD, Lee C, Petrichenko A, Hematti P, Brazauskas R, Jobe SM, Hari PN, Wilcox DA. Platelet-Targeted Gene Therapy for Hemophilia A with Inhibitor History. *N Engl J Med*. 2025 Jan 23;392(4):412-414. PMID: PMC11756741

Editorials, Letters To Editor, Other

1. **Johnson BD**. Alloantigen-specific regulatory T cells, *Blood*, 103:400, 2004.
2. Hallett W, **Johnson B**. Exploiting arginase to prevent GVHD, *Blood*, 116:5440, 2010.
3. **Johnson BD**. Exciting new murine model of cGVHD. *Blood*. 2012 Feb 09;119(6):1331-2.
4. Kindt N, Preillon J, Kaltner H, Gabius HJ, Chevalier D, Rodriguez A, **Johnson BD**, Megalizzi V, Decaestecker C, Laurent G, Saussez S. Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies. *J Cancer Res Clin Oncol*. 2013 May;139(5):727-37.
5. Barr KM, Jing W, Hallett WH, Gershan JA, **Johnson BD**. Examining T cells at vaccine sites of tumor-bearing hosts provides insights to dysfunctional T-cell immunity. *J Immunother*. 2013 Jan;36(1):41-51. PMID: PMC3521867

Abstracts

1. Jing W, Yan X, Orentas RJ, **Johnson BD**. Syngeneic Neuroblastoma Cells Transiently-Transfected with

- Plasmid DNA Vectors Encoding a Panel of Immune Stimulatory Molecules Can Induce Anti-Tumor Immunity Early after BMT. *Biol Blood Marrow Tr.* Feb 2006;13(suppl 1)(2):93.
2. Zhou Q, Orentas RJ, **Johnson BD**. Determining the Cellular Immune Response to a Subcutaneous Cell-Based Vaccine for Neuroblastoma. *J Immunol.* 2006 Apr 1;176 Suppl:S1-322.
 3. Orentas R, Yan X, **Johnson B**. Tumor-Derived Macrophage Migration Inhibitory Factor (MIF) Inhibits Lymphocyte Activation. *J Immunol.* 2006 Apr 1;176 Suppl:S1-322.
 4. **Johnson BD**, Jing W, Orentas RJ. CD25+ Regulatory T Cell Inhibition Enhances Vaccine-Induced Immunity to Neuroblastoma. *J Immunother.* 2006 Nov/Dec;29(6):665-666.
 5. Jing W, Orentas RJ, **Johnson BD**. Vaccine-Induced Anti-Neuroblastoma Immunity Early after HSCT Arises in the Presence of Foxp3+CD25+CD4+ T Cells. *Blood (ASH Annual Meeting Abstracts)*; Nov 2006;108:3692.
 6. Orentas R, Zheng J, Kohler M.E, Khan J, **Johnson B**: Discovery of New Immunologic Targets in Neuroblastoma by Vaccination in the Context of Regulatory T Cell Depletion: Immunodominance of the DEK Oncogene. Presented at the Advances in Neuroblastoma Research 2006 Meeting, Los Angeles, CA, May 17-20, 2006
 7. Orentas RJ, Jing W, Yan X, **Johnson BD**. Effective Immunotherapy for Neuroblastoma Requires HSCT and T Cell Transfer. *Biol Blood Marrow Tr.* Feb 2007,13(suppl)(2):29.
 8. Jing W, Yan X, Orentas RJ, **Johnson BD**. A Combination of Hematopoietic Stem Cell Transplantation (HSCT), Adoptive Immunotherapy, and Tumor Vaccination can Eliminate Established Tumor. *J Immunother.* Nov/Dec 2007;30(8):870.
 9. Zhou Q, Yan X, Orentas RJ, **Johnson BD**. Tumor-Derived Macrophage Migration Inhibitory Factor (MIF) Inhibits Immune Reactivity to Neuroblastoma In Vivo. *J Immunother.* Nov/Dec 2007;30(8):890.
 10. Yan X, **Johnson BD**, Orentas RJ. A Cell-Based Vaccine for Neuroblastoma Induces VLA-2 (CD49b) on CD8+ T Effector/Memory cells Via CD137L. *J Immunother.* 2007 Nov/Dec;30(8):867.
 11. Doffek K, Yan X, Sugg SL, **Johnson B**, Shilyansky J: Targeting Phosphatidylserine Promotes Immunity to Neuroblastoma. Presented at the American Association for Cancer Research annual meeting, Los Angeles, CA, April 14-18, 2007.
 12. Hallett WHD, Drobyski WR, **Johnson BD**. B7-H1 Blockade Enhances Immunotherapy for Multiple Myeloma. AIC2009 Program Booklet, p39, <http://autumnimmunology.org/flipbook/AIC2009ProgramBook/index.html>.
 13. Barr K, **Johnson BD**. Neuroblastoma Suppresses Anti-Tumor Immune Responses at Vaccine Sites. AIC2010 Program Booklet, p71, <http://autumnimmunology.org/flipbook/AIC2010ProgramBook/index.html>.
 14. Jing W, Yan X, Orentas RJ, **Johnson BD**: A Combination of Hematopoietic Stem Cell Transplantation (HSCT), Adoptive Immunotherapy and Tumor Vaccination can Eliminate Established Tumor. Presented at the Annual Meeting for the International Society for Biological Therapy of Cancer, Boston, MA, November 1-4, 2007.
 15. Gershan J, Yan X, **Johnson BD**: Immune Suppression is Transferred by Exposure to Supernatant from MIF Overexpressing Tumor. Presented at the AACR special conference entitled Tumor Immunology: New Perspectives, Miami, FL, December 2-5, 2008.
 16. Kohler ME, Chen Q, Hallett W H, **Johnson BD**: Induction of "Stemness" Genes in CDS T Cells after Vaccination of Tumor-Free Mice with a Cell-Based Vaccine . Presented at the AACR special conference entitled "Tumor Immunology: New Perspectives", Miami , FL, December 2-5, 2008
 17. Jing W, **Johnson BD**. Mechanisms of CD8 Memory Loss to Neuroblastoma after Autologous Hematopoietic Stem Cell Transplantation. *J Immunother.* Nov-Dec 2009;32(9):944.
 18. Kearl T, **Johnson BD**. Indoleamine 2,3-Dioxygenase Expression by Murine T Cells Following In Vitro Exposure to Tumor Culture Supernatant. *J Immunother.* Nov-Dec 2009;32(9):988.
 19. Jing W, **Johnson BD**. Depletion of CD4 T Cells Leads to Increased Tumor Immunity after HSCT Immunotherapy but Results in Loss of Memory. *Biol Blood Marrow Tr.* Feb 2009;15(2 suppl):83-84.
 20. Hallett WHD, Drobyski WR, **Johnson BD**. Blockade of the PD-1 Pathway Improves Immunotherapy for Myeloma. *J Immunother.* Dec 2010;33(8):870.
 21. Hallett WHD, Drobyski WR, **Johnson BD**. Inhibiting Immune Suppressive Pathways to Improve Immunotherapy for Myeloma. *Biology of Blood and Marrow Transplantation.* Feb 2011;17(2 suppl):S178-S179.
 22. Barr K, **Johnson BD**: Examining T Cells at the Vaccine Sites of Tumor-Bearing Hosts Provide Insights to Dysfunctional Tumor Immunity Presented at a National Cancer Institute sponsored meeting entitled "Cancer Immunology and Immunotherapy: Building on Success", Bethesda, MD, September 22-23,

2011

23. Kearn T, **Johnson BD**: Programmed Death Receptor as a Marker of Tumor- Reactive Cells in a Murine Model of Multiple Myeloma. Presented at a National Cancer Institute sponsored meeting entitled "Cancer Immunology and Immunotherapy: Building on Success", Bethesda, MD, September 22-23, 2011.
24. Kearn TJ, Jing W, **Johnson BD**: PD-1/PD-L1 Blockade after Transient Lymphodepletion to Treat Myeloma. Oral presentation at the Annual Meeting for the Society for Immunotherapy of Cancer (SITC), Bethesda, MD, October 26-28, 2012
25. Gershan J, Barr K, Weber J, **Johnson BD**: Cyclophosphamide in Combination with Tumor Lysate and TLR 9 Ligand Regresses Murine, Neuroblastoma. Presented at the Annual Meeting for the Society for Immunotherapy of Cancer (SITC), National Harbor, MD, November 7-10, 2013.
26. Jing W, Weber J, Tlomak D, McOlash L, Gershan J, Sabatos-Peyton C, **Johnson BD**: Combined Immune Checkpoint Protein Blockade and Lymphodepletion as Immunotherapy for Myeloma. Submitted for presentation at the Federation of Clinical Immunology Societies annual meeting in Chicago, IL, June, 2014
27. Jing W, Gershan JA, Weber J, Tlomak D, McOlash L, Sabatos-Peyton C, **Johnson BD**. Combined Immune Checkpoint Protein Blockade and Lymphodepletion as Immunotherapy for Myeloma. 43rd Annual Autumn Immunology Conference, Chicago, IL. Nov 2014
28. Tsai S., Aldakkak M., McOlash L., Grewal J., **Johnson B.**, Evans D., Mackinnon A.C., Gershan J.: Peripheral Immune Biomarkers as a Predictor of Pancreatic Cancer Progression. Presented at the AACR special conference titled "Pancreatic Cancer: Advances in Science and Clinical Care, Orlando, FL, May 12-15, 2016.
29. Jing W., Gershan J., Blitzer G., Weber J., McOlash L., and **Johnson B.D.**: Adoptive Transfer of Ex Vivo-Expanded PD-1+CD8+ and CD4+ T Cells Eliminates Myeloma in Mice. Presented at the Annual Meeting for the Society for Immunotherapy of Cancer (SITC), National Harbor, MD, November 11-13, 2016